Optimizing second-line therapy for chronic myeloid leukemia.
Indian J Cancer
;
2012 Jan-Mar; 49(1): 46-56
Artículo
en Inglés
| IMSEAR
| ID: sea-144551
ABSTRACT
Treatment of chronic myeloid leukemia has evolved from symptom control to long-term disease-free survival with cure potentially round the corner. This required faster, deeper, and longer response. Optimizing treatment decisions therefore requires clear understanding of and strict implementation of guidelines for shift from imatinib. In patients who are resistant to or intolerant of imatinib, second-line TKIs have to be selected carefully. Currently available data show comparable efficacy between nilotinib and dasatinib. With a better safety profile (especially with respect to grade 3 or 4 hematologic toxicity and clinically relevant non-hematologic toxicities), nilotinib becomes the preferred choice in most instances.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Piperazinas
/
Pirimidinas
/
Tiazoles
/
Proteínas Tirosina Quinasas
/
Humanos
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Aberraciones Cromosómicas
/
Proteínas de Fusión bcr-abl
/
Resultado del Tratamiento
/
Supervivencia sin Enfermedad
Tipo de estudio:
Guía de Práctica Clínica
/
Estudio pronóstico
Idioma:
Inglés
Revista:
Indian J Cancer
Año:
2012
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS